After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
Firce-1 is scrapped after showing dismal response rates and patient deaths.
On a wing and a prayer Leap heads for phase 3.
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
But the new focus on a predictive biomarker could cut the market in half.
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
Opdivo and Yervoy succeed again, but the US path remains unclear.
